BridgeMD
New treatment option for Attention Deficit Hyperactivity Disorder
Official title Treatment of ADHD Using High and Low Frequency Paired Associative Deep Transcranial Magnetic Stimulation
ClinicalTrials.gov ID: NCT07105475
What this study is testing
- What it's testing
- This study investigates the effects of high and low-frequency paired associative deep transcranial magnetic stimulation (dTMS) on adults with Attention Deficit Hyperactivity Disorder (ADHD). The study aims to explore whether targeting the prefrontal cortex with paired stimulation can improve symptoms of ADHD by balancing cortical arousal between the brain hemispheres.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Men and women aged 21-65.
- Aligned with the diagnosis of ADHD according to the criteria of the DSM-5.
- Participants taking medication for the treatment of attention deficit hyperactivity disorder will be asked, starting one week before the start of the...
- Give their written and oral consent to participate in the study.
You likely can't join if
- Additional active psychiatric disorders in Axis I of the DSM-5.
- Antipsychotic treatment, antidepressants, or mood stabilizers.
- History of intolerance to TMS.
- Diagnosis of severe personality disorder according to the DSM-5.
- Current suicidal tendency.
- High and uncontrolled blood pressure.
See the full eligibility criteria
- Men and women aged 21-65.
- Aligned with the diagnosis of ADHD according to the criteria of the DSM-5.
- Participants taking medication for the treatment of attention deficit hyperactivity disorder will be asked, starting one week before the start of the treatment until the end, to take Ritalin IR 10mg (provided that the...
- Give their written and oral consent to participate in the study.
- Additional active psychiatric disorders in Axis I of the DSM-5.
- Antipsychotic treatment, antidepressants, or mood stabilizers.
- History of intolerance to TMS.
- Diagnosis of severe personality disorder according to the DSM-5.
- Current suicidal tendency.
- High and uncontrolled blood pressure.
- History of epilepsy, seizures or febrile seizures.
- History of epilepsy or seizures in first degree relatives.
- History of a head injury or major stroke that produced impairment.
- History of metal in the head (outside the oral cavity).
- History of surgery involving metal implants or a known history of metal particles in the eye, pacemakers, hearing aid implantation, use of neurostimulators, or any medical pump.
- History of drug or alcohol addiction.
- Inability to adequately communicate with the examiner.
- Participation in another medical study at the time of conducting the experiment or 3 months before it.
- Inability of the subject to sign a consent form.
- Pregnancy or not giving a commitment not to get pregnant during the study period or having sex without using contraceptives.
The study team makes the final eligibility decision.
Where it's taking place
- Beersheba, Israel
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Beersheba, Israel. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.